{"id":31168,"date":"2026-02-27T11:54:19","date_gmt":"2026-02-27T06:24:19","guid":{"rendered":"https:\/\/www.niir.org\/blog\/?p=31168"},"modified":"2026-02-27T11:54:22","modified_gmt":"2026-02-27T06:24:22","slug":"biopharma-shakti-scheme-india","status":"publish","type":"post","link":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/","title":{"rendered":"Biopharma SHAKTI Scheme Explained: \u20b910,000 Crore Government Push for Biologics Manufacturing"},"content":{"rendered":"<p><em><strong>Biopharma SHAKTI Scheme India<\/strong><\/em><\/p>\n<p>India is entering a decisive phase in the industrial growth story. With the announcement of the \u20b910,000 crore Biopharma SHAKTI Programme, the Government of India has clearly indicated that there is a shift &#8211; from volume-led generic drug manufacturing to high value biologics, biosimilars and advanced therapeutic manufacture.<\/p>\n<p>Unlike previous healthcare initiatives that were aimed almost wholly towards the access and affordability of medicines, Biopharma SHAKTI is quite fundamentally a manufacturing-led industrial policy. For entrepreneurs, MSME, manufacturing consultants and project investors, this initiative is a rare combination of policy support combined with import substitution demand as well as global export opportunity.<\/p>\n<p>According to official updates released by the Press Information Bureau under the Ministry of Science &amp; Technology, the programme is designed to develop national capabilities in biologics production, biosimilar production, clinical research infrastructure and advanced therapy production &#8211; a move which will put India firmly into global biopharma value chains.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Read_More_Our_Books\" >Read More: Our Books<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#From_Generic_Dominance_to_Biopharma_Sovereignty\" >From Generic Dominance to Biopharma Sovereignty<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Key_Objectives_of_Biopharma_SHAKTI_Programmed\" >Key Objectives of Biopharma SHAKTI Programmed<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Read_More_Business_Plans_Project_Profiles\" >Read More: Business Plans \/ Project Profiles<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#High_Potential_Manufacturing_Opportunities_for_Enterprising_People\" >High Potential Manufacturing Opportunities for Enterprising People<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#1_Biosimilar_Manufacturing_Facilities\" >1. Biosimilar Manufacturing Facilities<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#2_Bioprocess_Equipment_Manufacturing_MSME_Opportunity\" >2. Bioprocess Equipment Manufacturing (MSME Opportunity)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#3_Enzyme_and_Cell_Culture_Media_Manufacture\" >3. Enzyme and Cell Culture Media Manufacture<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Read_More_Startup_Selector\" >Read More: Startup Selector<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#4_Contract_Development_Manufacturing_Organizations_CDMOs\" >4. Contract Development &amp; Manufacturing Organizations (CDMOs)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Market_Signals_Favorable_to_Investment_Decisions\" >Market Signals Favorable to Investment Decisions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Read_More_Biopharma_AYUSH_Manufacturing_New_Business_Opportunities_After_Budget_2026\" >Read More: Biopharma &amp; AYUSH Manufacturing: New Business Opportunities After Budget 2026<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Scalability_and_Profitability_for_Biopharma_Manufacturing\" >Scalability and Profitability for Biopharma Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Strategic_Lessons_from_Industry_Leaders\" >Strategic Lessons from Industry Leaders<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Importance_of_Detailed_Feasibility_Studies\" >Importance of Detailed Feasibility Studies<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Read_More_Top_15_Chemical_Manufacturing_Business_Ideas_in_India_with_Huge_Import_Substitution_Potential\" >Read More: Top 15 Chemical Manufacturing Business Ideas in India with Huge Import Substitution Potential<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Conclusion_A_Decade-Defining_Manufacturing_Opportunity\" >Conclusion: A Decade-Defining Manufacturing Opportunity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#Commonly_Asked_Questions_FAQs\" >Commonly Asked Questions (FAQs)<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Read_More_Our_Books\"><\/span>Read More: <a href=\"https:\/\/www.niir.org\/books\/category\">Our Books<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<h2><span class=\"ez-toc-section\" id=\"From_Generic_Dominance_to_Biopharma_Sovereignty\"><\/span>From Generic Dominance to Biopharma Sovereignty<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>India is known all over the world as the &#8220;pharmacy of the world&#8221; because of its leadership in the export of generic drugs. However, advanced biologics &#8211; such as monoclonal antibodies, recombinant proteins, insulin analogues and cell-based therapies &#8211; remain strongly import-dependent.<\/p>\n<p><strong>Why Biologics Are Different<\/strong><\/p>\n<p>Unlike small molecule generics, biologics require:<\/p>\n<ul>\n<li>Large-scale fermentation systems.<\/li>\n<li>Mammalian cell culture bioreactors<\/li>\n<li>Aseptic facilities that are cleanroom compliant<\/li>\n<li>Complicated downstream purification technologies<\/li>\n<\/ul>\n<p>These high entry barriers have served to constrain domestic capacity in the past. The Biopharma SHAKTI Programme is a direct response to this gap and aims to develop policy supported demand visibility, research infrastructure and manufacturing incentives.<\/p>\n<p>This strategy is very much a repeat of previous government-driven successes such as:<\/p>\n<ul>\n<li>Solar PV module manufacturing<\/li>\n<li>Mobile handset assembly<\/li>\n<li>Electronics and semiconductors clusters<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Objectives_of_Biopharma_SHAKTI_Programmed\"><\/span>Key Objectives of Biopharma SHAKTI Programmed<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The programme is designed to provide long-term manufacturing competitiveness, and not short term subsidies. Its core objectives include:<\/p>\n<ul>\n<li>Developing domestic biologics manufacturing capacity<\/li>\n<li>Reducing import dependency on high value therapeutics<\/li>\n<li>Aiding indigenous biosimilar development<\/li>\n<li>Building clinical trial and translational research infrastructure<\/li>\n<li>Enabling the production of advanced therapies (cell and gene therapies)<\/li>\n<\/ul>\n<p>For industrial investors this creates predictable institutional demand &#8211; an important consideration for capital-intensive manufacturing decisions.(Biopharma SHAKTI Scheme India)<\/p>\n<h3 style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Read_More_Business_Plans_Project_Profiles\"><\/span>Read More: <a href=\"https:\/\/www.niir.org\/business-plan\">Business Plans \/ Project Profiles<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<h2><span class=\"ez-toc-section\" id=\"High_Potential_Manufacturing_Opportunities_for_Enterprising_People\"><\/span>High Potential Manufacturing Opportunities for Enterprising People<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Biosimilar_Manufacturing_Facilities\"><\/span>1. Biosimilar Manufacturing Facilities<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Biosimilars are the fastest-growing segment in the global pharmaceuticals. As patents expire on blockbuster biologics, demand for cost-effective biosimilars continues to increase.<\/p>\n<p><strong>Why biosimilar manufacturing is attractive:<\/strong><\/p>\n<ul>\n<li>High entry barriers =competition is reduced<\/li>\n<li>Strong pricing power, relative to generics<\/li>\n<li>Long product life cycles<\/li>\n<li>Institutional and export-oriented demands<\/li>\n<\/ul>\n<p>India has already had success stories. Biocon Ltd., which was founded by Kiran Mazumdar-Shaw, has jumped in early with biosimilars by investing on fermentation technology and insulin analogues- which enable entry into regulated global markets.<\/p>\n<p>New entrants can replicate this success by focusing on niche biosimilars as opposed to mass portfolios.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Bioprocess_Equipment_Manufacturing_MSME_Opportunity\"><\/span>2. Bioprocess Equipment Manufacturing (MSME Opportunity)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Major portion of bioprocess equipment of India is currently being imported, which include:<\/p>\n<ul>\n<li>Bioreactors and fermenters<\/li>\n<li>Chromatography skids<\/li>\n<li>Sterile filtration systems<\/li>\n<li>CIP\/SIP automation modules<\/li>\n<\/ul>\n<p>This creates an enormous opportunity for manufacturing driven by engineering MSMEs to manufacture:<\/p>\n<ul>\n<li>Stainless steel bioreactor vessels<\/li>\n<\/ul>\n<ul>\n<li>Process piping and aseptic tanks<\/li>\n<li>Utility automation systems<\/li>\n<\/ul>\n<p>A classic example of vertical integration is that of Serum Institute of India, run by Adar Poonawalla, which has invested in fermentation infrastructure from early stages, instead of relying on imported equipment.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Enzyme_and_Cell_Culture_Media_Manufacture\"><\/span>3. Enzyme and Cell Culture Media Manufacture<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For first-generation entrepreneurs, upstream biopharma inputs provide a better entry point with fewer risks.<\/p>\n<p>Manufacturing opportunities include:<\/p>\n<ul>\n<li>Amino acid nutrient blends<\/li>\n<li>Mammalian cell culture Growth Media<\/li>\n<li>Enzymes &#8211; recombinant and specialty enzymes<\/li>\n<\/ul>\n<p><strong>Advantages of this segment:<\/strong><\/p>\n<ul>\n<li>Lower regulatory burden<\/li>\n<li>Shorter gestation periods<\/li>\n<li>Smaller cleanroom requirements<\/li>\n<li>High institutional demand reoccurs<\/li>\n<\/ul>\n<p>These products are the backbone of any biologics manufacturing process.<\/p>\n<h3 style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Read_More_Startup_Selector\"><\/span>Read More: <a href=\"https:\/\/www.niir.org\/startup-selector\">Startup Selector<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/Gemini_Generated_Image_rf5tcgrf5tcgrf5t-687x1024.png\" sizes=\"(max-width: 687px) 100vw, 687px\" srcset=\"https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/Gemini_Generated_Image_rf5tcgrf5tcgrf5t-687x1024.png 687w, https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/Gemini_Generated_Image_rf5tcgrf5tcgrf5t-201x300.png 201w, https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/Gemini_Generated_Image_rf5tcgrf5tcgrf5t-768x1145.png 768w, https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/Gemini_Generated_Image_rf5tcgrf5tcgrf5t-512x763.png 512w, https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/Gemini_Generated_Image_rf5tcgrf5tcgrf5t.png 848w\" alt=\"Biopharma SHAKTI Scheme India\" width=\"687\" height=\"1024\" \/><\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Contract_Development_Manufacturing_Organizations_CDMOs\"><\/span>4. Contract Development &amp; Manufacturing Organizations (CDMOs)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>With more than 1,000 accredited clinical trial sites in the pipeline under the SHAKTI ecosystem, there should be a huge demand for outsourcing biomanufacturing.<\/p>\n<p>CDMO facilities can cater to:<\/p>\n<ul>\n<li>Vaccine intermediates<\/li>\n<li>Therapeutic proteins<\/li>\n<li>Diagnostic biologics<\/li>\n<\/ul>\n<p>Companies like Syngene International have shown just how scalable and lucrative this model can be if it is paired with global pharmaceutical clients.(Biopharma SHAKTI Scheme India)<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Market_Signals_Favorable_to_Investment_Decisions\"><\/span>Market Signals Favorable to Investment Decisions<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<td>\n<p><strong>Indicator<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Investor Insight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\n<p>Import Dependence<\/p>\n<\/td>\n<td>\n<p>High in advanced biologics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Government Procurement<\/p>\n<\/td>\n<td>\n<p>Long-term institutional contracts<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Clinical Research<\/p>\n<\/td>\n<td>\n<p>1,000+ accredited sites planned<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Infrastructure<\/p>\n<\/td>\n<td>\n<p>Upgraded NIPER facilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Regulatory Alignment<\/p>\n<\/td>\n<td>\n<p>Faster CDSCO approvals<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>In sum, these factors make it less risky for startups to plan capital intensive healthcare manufacturing.<\/p>\n<h3 style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Read_More_Biopharma_AYUSH_Manufacturing_New_Business_Opportunities_After_Budget_2026\"><\/span>Read More: <a href=\"https:\/\/www.entrepreneurindia.co\/blogs\/biopharma-ayush-manufacturing\/\">Biopharma &amp; AYUSH Manufacturing: New Business Opportunities After Budget 2026<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<h2><span class=\"ez-toc-section\" id=\"Scalability_and_Profitability_for_Biopharma_Manufacturing\"><\/span>Scalability and Profitability for Biopharma Manufacturing<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>From a techno-economic point of view, biopharma projects are very different from the classical pharma plants:<\/p>\n<ul>\n<li>More capital investment per facility<\/li>\n<li>Extended commissioning and validation times<\/li>\n<li>Strong pricing control after approval &#8211;<\/li>\n<li>Significantly higher export margins<\/li>\n<\/ul>\n<p>Once approved, biologics have limited competition because of process complexity, which has made the IRRs superior compared to generic drug manufacturing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Strategic_Lessons_from_Industry_Leaders\"><\/span>Strategic Lessons from Industry Leaders<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Successful Indian biopharma leaders have the following decision frameworks common:<\/p>\n<ul>\n<li>Entry into under-served technology segments<\/li>\n<li>Or &#8220;If you want to get somewhere&#8221; &#8211; &#8220;This is what you need to do&#8221;.<\/li>\n<li>Leveraging the regulation regulator quality barriers<\/li>\n<li>Long-term infrastructure mentality<\/li>\n<\/ul>\n<p>These principles are still very relevant for new entrepreneurs considering SHAKTI aligned projects.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Importance_of_Detailed_Feasibility_Studies\"><\/span>Importance of Detailed Feasibility Studies<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Biopharma projects require strict pre-investment analysis including:<\/p>\n<ul>\n<li>Cleanroom and utility design<\/li>\n<li>Process flow and validation planning<\/li>\n<li>Raw material sourcing strategies<\/li>\n<li>Key issues will encompass the following:<\/li>\n<\/ul>\n<p>At Niir Project Consultancy Services (NPCS), we specialize in preparation of Market Survey cum Detailed Techno-Economic Feasibility Reports (DPRs) on:<\/p>\n<ul>\n<li>Manufacturing processes<\/li>\n<li>Machinery and raw materials<\/li>\n<li>Capacity planning<\/li>\n<li>Project costing &amp; financial modelling<\/li>\n<li>Profitability and Internal Rate of Return (IRR) analysis<\/li>\n<\/ul>\n<p>Our goal is to assist investors in mitigating risk and maximizing scalability before capital deployment.<\/p>\n<h3 style=\"text-align: center;\"><span class=\"ez-toc-section\" id=\"Read_More_Top_15_Chemical_Manufacturing_Business_Ideas_in_India_with_Huge_Import_Substitution_Potential\"><\/span>Read More: <a href=\"https:\/\/npcsblog.com\/chemical-manufacturing-business-ideas-in-india\/\">Top 15 Chemical Manufacturing Business Ideas in India with Huge Import Substitution Potential<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe  id=\"_ytid_65652\"  width=\"750\" height=\"421\"  data-origwidth=\"750\" data-origheight=\"421\" src=\"https:\/\/www.youtube.com\/embed\/NoAliG5d2vw?enablejsapi=1&#038;autoplay=0&#038;cc_load_policy=0&#038;cc_lang_pref=&#038;iv_load_policy=1&#038;loop=0&#038;rel=1&#038;fs=1&#038;playsinline=0&#038;autohide=2&#038;theme=dark&#038;color=red&#038;controls=1&#038;disablekb=0&#038;\" class=\"__youtube_prefs__  epyt-is-override  no-lazyload\" title=\"YouTube player\"  allow=\"fullscreen; accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen data-no-lazy=\"1\" data-skipgform_ajax_framebjll=\"\"><\/iframe>\n<\/div><\/figure>\n\n\n<h2 class=\"wp-block-heading\" id=\"conclusion-a-decadedefining-manufacturing-opportunity\"><span class=\"ez-toc-section\" id=\"Conclusion_A_Decade-Defining_Manufacturing_Opportunity\"><\/span>Conclusion: A Decade-Defining Manufacturing Opportunity<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<p>The <strong>Biopharma SHAKTI Programme<\/strong> marks a turning point in India\u2019s industrial strategy\u2014moving decisively from generic dominance to <strong>advanced therapeutic manufacturing leadership<\/strong>.<\/p>\n\n\n\n<p>For entrepreneurs aligned with <strong>policy-driven industrialization cycles<\/strong>, this initiative opens multiple entry points across the biopharma value chain. In capital-intensive sectors, <strong>government-backed ecosystem support often determines long-term viability<\/strong>.<\/p>\n\n\n\n<p>This programme has the potential to define <strong>India\u2019s healthcare manufacturing landscape for the next decade<\/strong>.(Biopharma SHAKTI Scheme India)<\/p>\n\n\n<h2 class=\"wp-block-heading\" id=\"commonly-asked-questions-faqs\"><span class=\"ez-toc-section\" id=\"Commonly_Asked_Questions_FAQs\"><\/span>Commonly Asked Questions (FAQs)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<p><strong>Q1. Is biopharma manufacturing for MSMEs?<\/strong><\/p>\n\n\n\n<p>Yes. MSMEs may come in from bioprocess equipment, enzymes, culture media, and component manufacturing.<\/p>\n\n\n\n<p><strong>Q2. What are the Biggest Risks in Biopharma Projects?<\/strong><\/p>\n\n\n\n<p>Regulatory approvals, technology transfer costs, and long validation timelines.<\/p>\n\n\n\n<p><strong>Q3. How long is the gestation period?<\/strong><\/p>\n\n\n\n<p>Normally larger than traditional pharma plants because of complicated validation needs.<\/p>\n\n\n\n<p><strong>Q4. Can startups get in by contract manufacturing?<\/strong><\/p>\n\n\n\n<p>Yes. CDMO models provide revenue without having all the product development risk.<\/p>\n\n\n\n<p><strong>Q5. Why are biologics more profitable than generics?<\/strong><\/p>\n\n\n\n<p>Higher entry barriers and little competition gives better pricing control and margins.<\/p>\n","protected":false},"excerpt":{"rendered":"Biopharma SHAKTI Scheme India India is entering a decisive phase in the industrial growth story. With the announcement&hellip;","protected":false},"author":15,"featured_media":31169,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"iawp_total_views":40,"csco_display_header_overlay":false,"csco_singular_sidebar":"","csco_page_header_type":"","footnotes":""},"categories":[16847,17377],"tags":[18112,17873,17871,18113],"industry":[],"class_list":{"0":"post-31168","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-pharmaceutical-industry","8":"category-government-schemes-policies","9":"tag-biologics","10":"tag-biosimilar-meaning","11":"tag-biosimilars","12":"tag-molecular-bio-products","13":"cs-entry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biopharma SHAKTI Scheme India: \u20b910,000 Cr Boost for Biologics<\/title>\n<meta name=\"description\" content=\"Learn how the Biopharma SHAKTI Scheme India is transforming biologics manufacturing in India with \u20b910,000 crore investment, MSME.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biopharma SHAKTI Scheme India: \u20b910,000 Cr Boost for Biologics\" \/>\n<meta property=\"og:description\" content=\"Learn how the Biopharma SHAKTI Scheme India is transforming biologics manufacturing in India with \u20b910,000 crore investment, MSME.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/\" \/>\n<meta property=\"og:site_name\" content=\"Niir Project Consultancy Services\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T06:24:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T06:24:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/ChatGPT-Image-Feb-27-2026-11_28_08-AM-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Industrial Insights Desk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Industrial Insights Desk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biopharma SHAKTI Scheme India: \u20b910,000 Cr Boost for Biologics","description":"Learn how the Biopharma SHAKTI Scheme India is transforming biologics manufacturing in India with \u20b910,000 crore investment, MSME.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/","og_locale":"en_US","og_type":"article","og_title":"Biopharma SHAKTI Scheme India: \u20b910,000 Cr Boost for Biologics","og_description":"Learn how the Biopharma SHAKTI Scheme India is transforming biologics manufacturing in India with \u20b910,000 crore investment, MSME.","og_url":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/","og_site_name":"Niir Project Consultancy Services","article_published_time":"2026-02-27T06:24:19+00:00","article_modified_time":"2026-02-27T06:24:22+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/ChatGPT-Image-Feb-27-2026-11_28_08-AM-1024x683.png","type":"image\/png"}],"author":"Industrial Insights Desk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Industrial Insights Desk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#article","isPartOf":{"@id":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/"},"author":{"name":"Industrial Insights Desk","@id":"\/#\/schema\/person\/511a0780b0fbcfb5da823fe974507c77"},"headline":"Biopharma SHAKTI Scheme Explained: \u20b910,000 Crore Government Push for Biologics Manufacturing","datePublished":"2026-02-27T06:24:19+00:00","dateModified":"2026-02-27T06:24:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/"},"wordCount":1182,"image":{"@id":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#primaryimage"},"thumbnailUrl":"https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/ChatGPT-Image-Feb-27-2026-11_28_08-AM.png","keywords":["biologics","biosimilar meaning","biosimilars","molecular bio products"],"articleSection":["Pharmaceutical Business Ideas","Startup Policies, Subsidies &amp; Government Schemes"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/","url":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/","name":"Biopharma SHAKTI Scheme India: \u20b910,000 Cr Boost for Biologics","isPartOf":{"@id":"\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#primaryimage"},"image":{"@id":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#primaryimage"},"thumbnailUrl":"https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/ChatGPT-Image-Feb-27-2026-11_28_08-AM.png","datePublished":"2026-02-27T06:24:19+00:00","dateModified":"2026-02-27T06:24:22+00:00","author":{"@id":"\/#\/schema\/person\/511a0780b0fbcfb5da823fe974507c77"},"description":"Learn how the Biopharma SHAKTI Scheme India is transforming biologics manufacturing in India with \u20b910,000 crore investment, MSME.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.niir.org\/blog\/biopharma-shakti-scheme-india\/#primaryimage","url":"https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/ChatGPT-Image-Feb-27-2026-11_28_08-AM.png","contentUrl":"https:\/\/www.niir.org\/blog\/wp-content\/uploads\/2026\/02\/ChatGPT-Image-Feb-27-2026-11_28_08-AM.png","width":1536,"height":1024,"caption":"Government of India launches Biopharma SHAKTI Scheme to strengthen domestic biologics manufacturing ecosystem."},{"@type":"WebSite","@id":"\/#website","url":"\/","name":"Niir Project Consultancy Services","description":"Project Reports, Business Plan","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"\/#\/schema\/person\/511a0780b0fbcfb5da823fe974507c77","name":"Industrial Insights Desk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.niir.org\/blog\/wp-content\/litespeed\/avatar\/a8e01bf195ad079f8a3644cf909ad1b2.jpg?ver=1777551994","url":"https:\/\/www.niir.org\/blog\/wp-content\/litespeed\/avatar\/a8e01bf195ad079f8a3644cf909ad1b2.jpg?ver=1777551994","contentUrl":"https:\/\/www.niir.org\/blog\/wp-content\/litespeed\/avatar\/a8e01bf195ad079f8a3644cf909ad1b2.jpg?ver=1777551994","caption":"Industrial Insights Desk"},"description":"Industrial Insights Desk is a dedicated editorial and research team focused on delivering reliable, practical, and industry-oriented content on manufacturing, project consultancy, and business opportunities. The desk brings together experienced professionals from the fields of industrial consulting, publishing, and entrepreneurship development to provide well-researched insights for investors, startups, and industry stakeholders. The team comprises: Ajay Kumar Gupta, Editor-in-Chief of Entrepreneur India Magazine, with extensive experience in industrial publishing, business advisory, and promoting entrepreneurship in India. P. K. Chattopadhyay, B.Tech (F.T.B.E.), P.G.D., Senior Project Consultant, with deep technical expertise in project planning, industrial processes, and feasibility analysis across multiple sectors. Udant Gupta, Joint Editor of Entrepreneur India Magazine, actively involved in content development, market research, and digital outreach for emerging business trends. Industrial Insights Desk aims to bridge the gap between knowledge and execution by offering actionable content, detailed project insights, and up-to-date information aligned with current industry demands.","sameAs":["https:\/\/www.linkedin.com\/company\/121053929\/"]}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/posts\/31168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/comments?post=31168"}],"version-history":[{"count":5,"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/posts\/31168\/revisions"}],"predecessor-version":[{"id":31175,"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/posts\/31168\/revisions\/31175"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/media\/31169"}],"wp:attachment":[{"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/media?parent=31168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/categories?post=31168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/tags?post=31168"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.niir.org\/blog\/wp-json\/wp\/v2\/industry?post=31168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}